

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM822094

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
BIOQ PHARMA INCORPORATED		08/09/2017	Corporation: CALIFORNIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MADRYN HEALTH PARTNERS, LP		
<b>Street Address:</b>	c/o MADRYN ASSET MANAGEMENT, LP		
<b>Internal Address:</b>	330 MADISON AVENUE, 33rd FLOOR		
<b>City:</b>	NEW YORK		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10017		
<b>Entity Type:</b>	Limited Partnership: DELAWARE		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87831985	READYFUSOR	
<b>Serial Number:</b>	88357780	INVENIOUS	
<b>Serial Number:</b>	87173397	BIOQ PHARMA	
<b>Serial Number:</b>	87173410	BIOQ PHARMA	
<b>Serial Number:</b>	88958597	BIOQ PHARMA	
<b>Serial Number:</b>	88939015	SEDA-Q	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7043311159		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	704-331-1000		
<b>Email:</b>	jansnider@mvalaw.com, vangambrell@mvalaw.com		
<b>Correspondent Name:</b>	MOORE & VAN ALLEN PLLC		
<b>Address Line 1:</b>	100 NORTH TRYON STREET, SUITE 4700		
<b>Address Line 2:</b>	ATTN: IP DEPARTMENT		
<b>Address Line 4:</b>	CHARLOTTE, NORTH CAROLINA 28202		
<b>ATTORNEY DOCKET NUMBER:</b>	043094-000006		
<b>NAME OF SUBMITTER:</b>	James Van Cleave Gambrell		

OP \$165.00 87831985

<b>SIGNATURE:</b>	/James Van Cleave Gambrell/
<b>DATE SIGNED:</b>	07/05/2023
<b>Total Attachments: 4</b> source=IP Notice (Trademarks) - BioQ Pharma June 2023 (Executed)#page1.tif source=IP Notice (Trademarks) - BioQ Pharma June 2023 (Executed)#page2.tif source=IP Notice (Trademarks) - BioQ Pharma June 2023 (Executed)#page3.tif source=IP Notice (Trademarks) - BioQ Pharma June 2023 (Executed)#page4.tif	

NOTICE  
OF  
GRANT OF SECURITY INTEREST  
IN  
TRADEMARKS

United States Patent and Trademark Office

Ladies and Gentlemen:


Please be advised that pursuant to the Security Agreement dated as of August 9, 2017 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and Madryn Health Partners, LP, as Administrative Agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any trademark, trademark license or trademark application.

[Signature pages follow]

Very truly yours,

BIOQ PHARMA INCORPORATED

By:   
Name: Scott K. Wiersma  
Title: President & CEO

Acknowledged and Accepted:

ADMINISTRATIVE AGENT:

MADRYN HEALTH PARTNERS, LP,  
a Delaware limited partnership

By: MADRYN HEALTH ADVISORS, LP,  
its General Partner

By: MADRYN HEALTH ADVISORS GP, LLC,  
its General Partner

A handwritten signature in black ink, appearing to read 'Avinash Amin', with a stylized flourish at the end.

By:  
Name: Avinash Amin  
Title: Member

## Schedule 1

### Trademark Rights

<i>Jurisdiction</i>	<i>Mark</i>	<i>Registration Number</i>	<i>Filing Date</i>	<i>Serial / Application Number</i>
US	READYFUSOR		3/13/2018	87831985
US	INVENIOUS	6165044	3/26/2019	88357780
US	BIOQ PHARMA		9/16/2016	87173397
US	BIOQ PHARMA and Design		9/16/2016	87173410
US	BIOQ PHARMA		6/10/2020	88958597
US	SEDA-Q		5/29/2020	88939015
WIPO	INVENIOUS	1498063	9/18/2019	1498063
UK	ONE DOSE READYFUSOR	UK00913339651	10/8/2014	UK00913339651
UK	READYFUSOR	UK00913339651	10/8/2014	UK00913339676
UK	ROPIFUSOR	UK00913736053	2/13/2015	UK00913736053
UK	INVENIOUS	UK00801498063	9/18/2019	UK00801498063
AU	PROPOFUSOR	1980565	1/3/2019	1980565
AU	READYFUSOR	1892879	12/7/2017	1892879
AU	INVENIOUS	2050812	9/18/2019	2050812